APA (7th ed.) Citation

R, G., F, G., P, T., F, J., C, B., M, G., . . . R, D. S. (2026). [18F]FDG PET/CT as a biomarker for response evaluation in neoadjuvant treatment of early breast cancer: Could it become a game-changer in the scenario of the emerging (de)-escalation strategies? La Radiologia medica, 131(4), 582. https://doi.org/10.1007/s11547-025-02138-0

Chicago Style (17th ed.) Citation

R, Gerosa, et al. "[18F]FDG PET/CT as a Biomarker for Response Evaluation in Neoadjuvant Treatment of Early Breast Cancer: Could It Become a Game-changer in the Scenario of the Emerging (de)-escalation Strategies?" La Radiologia Medica 131, no. 4 (2026): 582. https://doi.org/10.1007/s11547-025-02138-0.

MLA (9th ed.) Citation

R, Gerosa, et al. "[18F]FDG PET/CT as a Biomarker for Response Evaluation in Neoadjuvant Treatment of Early Breast Cancer: Could It Become a Game-changer in the Scenario of the Emerging (de)-escalation Strategies?" La Radiologia Medica, vol. 131, no. 4, 2026, p. 582, https://doi.org/10.1007/s11547-025-02138-0.